FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Dexferrum Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Risk for Anaphylactic-type Reactions: Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran. Always have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during Dexferrum administration. Prior to the first therapeutic dose, administer a test Dexferrum dose of 0.5 mL intravenously at a gradual rate over at least five minutes. Although reactions are usually evident within a few minutes, observe patients for at least one hour before administering the therapeutic dose. During all Dexferrum administrations, observe patients for signs or symptoms of anaphylactic-type reactions. Fatal reactions have followed the test dose of iron dextran and have also occurred in situations where the test dose was tolerated. Use Dexferrum only in patients in whom clinical and laboratory investigations have established an iron deficient state not amenable to oral iron therapy.
The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies. Additionally, concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for reactions to an iron dextran product. The extent of risk for anaphylactic-type reactions following exposure to any specific iron dextran product is unknown and may vary among the products. Iron dextran products differ in chemical characteristics and may differ in clinical effects. Iron dextran products are not clinically interchangeable.
Delayed Reactions: Large intravenous doses, such as used with total dose infusions (TDI), have been associated with an increased incidence of adverse effects. The adverse effects frequently are delayed (1-2 days) reactions typified by one or more of the following symptoms: arthralgia, backache, chills, dizziness, moderate to high fever, headache, malaise, myalgia, nausea, and vomiting. The onset is usually 24-48 hours after administration and symptoms generally subside within 3-4 days. The etiology of these reactions is not known. The potential for a delayed reaction must be considered when estimating the risk/benefit of treatment.
The maximum daily dose should not exceed 2 mL undiluted iron dextran.
Risks in Patients with Underlying Conditions: Dexferrum should be used with extreme care in patients with serious impairment of liver function. It should not be used during the acute phase of infectious kidney disease.
Adverse reactions experienced following administration of Dexferrum may exacerbate cardiovascular complications in patients with pre-existing cardiovascular disease.
Carcinogenesis: A risk of carcinogenesis may attend the intramuscular injection of iron-carbohydrate complexes. Such complexes have been found under experimental conditions to produce sarcoma when large doses or small doses injected repeatedly at the same site were given to rats, mice, and rabbits, and possibly in hamsters.
The long latent period between the injection of a potential carcinogen and the appearance of a tumor makes it impossible to measure accurately the risk in man. There have, however, been several reports in the literature describing tumors at the injection site in humans who had previously received intramuscular injections of iron-carbohydrate complexes.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Dexferrum is indicated for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible.
History
There is currently no drug history available for this drug.
Other Information
DEXFERRUM® (IRON DEXTRAN INJECTION, USP) is a dark brown, slightly viscous sterile liquid complex of ferric oxyhydroxide for intravenous use. Each mL contains: 50 mg elemental iron as an iron dextran complex. Sodium chloride may have been added for tonicity. Water for injection q.s. pH (range 4.5-7.0) adjusted with hydrochloric acid and, if necessary, sodium hydroxide. Sterile, nonpyrogenic.
Therapeutic Class: Hematinic
Sources
Dexferrum Manufacturers
-
American Regent, Inc.
Dexferrum | American Regent, Inc.
Oral iron should be discontinued prior to administration of Dexferrum.
Dosage:I. Iron Deficiency Anemia: Periodic hematologic determination (hemoglobin and hematocrit) is a simple and accurate technique for monitoring hematological response, and should be used as a guide in therapy. It should be recognized that iron storage may lag behind the appearance of normal blood morphology. Serum iron, total iron binding capacity (TIBC) and percent saturation of transferrin are other important tests for detecting and monitoring the iron deficient state.
After administration of iron dextran complex, evidence of a therapeutic response can be seen in a few days as an increase in the reticulocyte count.
Although serum ferritin is usually a good guide to body iron stores, the correlation of body iron stores and serum ferritin may not be valid in patients on chronic renal dialysis who are also receiving iron dextran complex.
Although there are significant variations in body build and weight distribution among males and females, the accompanying table and formula represent a convenient means for estimating the total iron required. This total iron requirement reflects the amount of iron needed to restore hemoglobin concentration to normal or near normal levels plus an additional allowance to provide adequate replenishment of iron stores in most individuals with moderately or severely reduced levels of hemoglobin. It should be remembered that iron deficiency anemia will not appear until essentially all iron stores have been depleted. Therapy, thus, should aim at not only replenishment of hemoglobin iron but iron stores as well.
Factors contributing to the formula are shown below.
mg blood iron = mL blood x g hemoglobin x mg iron lb body weight lb body weight mL blood g hemoglobin
Blood volume...............65 mL/kg of body weight Normal hemoglobin (males and females)
over 15 kg (33 lbs)...............14.8 g/dl
15 kg (33 lbs) or less...........12 g/dl Iron content of hemoglobin...............0.34% Hemoglobin deficit WeightBased on the above factors, individuals with normal hemoglobin levels will have approximately 33 mg of blood iron per kilogram of body weight (15 mg/lb).
Note: The table and accompanying formula are applicable for dosage determinations only in patients with iron deficiency anemia; they are not to be used for dosage determinations in patients requiring iron replacement for blood loss.
TOTAL DEXFERRUM® REQUIREMENT FOR HEMOGLOBIN RESTORATION AND IRON STORES REPLACEMENT* Milliliter Requirement of Dexferrum Based On Observed
Hemoglobin of PATIENT
LEAN BODY
WEIGHT 3
(g/dl) 4
(g/dl) 5
(g/dl) 6
(g/dl) 7
(g/dl) 8
(g/dl) 9
(g/dl) 10
(g/dl) kg lb*Table values were calculated based on a normal adult hemoglobin of 14.8 g/dl for weights greater than 15 kg (33 lbs) and a hemoglobin of 12.0 g/dl for weights less than or equal to 15 kg (33 lbs).
5 11 3 3 3 3 2 2 2 2 10 22 7 6 6 5 5 4 4 3 15 33 10 9 9 8 7 7 6 5 20 44 16 15 14 13 12 11 10 9 25 55 20 18 17 16 15 14 13 12 30 66 23 22 21 19 18 17 15 14 35 77 27 26 24 23 21 20 18 17 40 88 31 29 28 26 24 22 21 19 45 99 35 33 31 29 27 25 23 21 50 110 39 37 35 32 30 28 26 24 55 121 43 41 38 36 33 31 28 26 60 132 47 44 42 39 36 34 31 28 65 143 51 48 45 42 39 36 34 31 70 154 55 52 49 45 42 39 36 33 75 165 59 55 52 49 45 42 39 35 80 176 63 59 55 52 48 45 41 38 85 187 66 63 59 55 51 48 44 40 90 198 70 66 62 58 54 50 46 42 95 209 74 70 66 62 57 53 49 45 100 220 78 74 69 65 60 56 52 47 105 231 82 77 73 68 63 59 54 50 110 242 86 81 76 71 67 62 57 52 115 253 90 85 80 75 70 64 59 54 120 264 94 88 83 78 73 67 62 57The total amount of Dexferrum in mL required to treat the anemia and replenish iron stores may be approximated as follows:
Adults and Children over 15 kg (33 lbs): See Dosage Table. Alternatively the total dose may be calculated:
Dose (mL) = 0.0442 (Desired Hb - Observed Hb) x LBW + (0.26 x LBW)
Based on: Desired Hb = the target Hb in g/dl.
Observed Hb = the patient's current hemoglobin in g/dl.
LBW = Lean body weight in kg. A patient's lean body weight (or actual body weight if less than lean body weight) should be utilized when determining dosage.
For males: LBW = 50 kg + 2.3 kg for each inch of patient's height over 5 feet
For females: LBW = 45.5 kg + 2.3 kg for each inch of patient's height over 5 feet
To calculate a patient's weight in kg when lbs are known:
patient's weight in pounds = weight in kilograms 2.2Children 5 -15 kg (11 -33 lbs): See Dosage Table.
Dexferrum should not normally be given in the first four months of life. (See PRECAUTIONS: Pediatric Use)
Alternatively the total dose may be calculated:
Dose (mL) = 0.0442 (Desired Hb - Observed Hb) x W + (0.26 x W)
Based on: Desired Hb = the target Hb in g/dl. (Normal Hb for Children 15 kg or less is 12 g/dl)
W = Weight in kg.
To calculate a patient's weight in kg when lbs are known:
patient's weight in pounds = weight in kilograms 2.2II. Iron Replacement for Blood Loss: Some individuals sustain blood losses on an intermittent or repetitive basis. Such blood losses may occur periodically in patients with hemorrhagic diatheses (familial telangiectasia; hemophilia; gastrointestinal bleeding) and on a repetitive basis from procedures such as renal hemodialysis.
Iron therapy in these patients should be directed toward replacement of the equivalent amount of iron represented in the blood loss. The table and formula described under I. Iron Deficiency Anemia are not applicable for simple iron replacement values.
Quantitative estimates of the individual's periodic blood loss and hematocrit during the bleeding episode provide a convenient method for the calculation of the required iron dose.
The formula shown below is based on the approximation that 1 mL of normocytic, normochromic red cells contains 1 mg of elemental iron:
Replacement iron (in mg) = Blood loss (in mL) x hematocrit
Example: Blood loss of 500 mL with 20% hematocrit Replacement Iron = 500 x 0.20 = 100 mg Dexferrum dose = 100 mg = 2 mL 50Administration: The total amount of Dexferrum required for the treatment of iron deficiency anemia or iron replacement for blood loss is determined from the table or appropriate formula (See Dosage).
Dexferrum is administered by intravenous injection. PRIOR TO THE FIRST DEXFERRUM THERAPEUTIC DOSE, ADMINISTER A TEST DOSE OF 0.5 ML INTRAVENOUSLY (See BOXED WARNING and PRECAUTIONS). ADMINISTER THE TEST DOSE AT A GRADUAL RATE OVER AT LEAST FIVE MINUTES. Although anaphylactic reactions known to occur following Dexferrum administration are usually evident within a few minutes, or sooner, it is recommended that a period of an hour or longer elapse before the remainder of the initial therapeutic dose is given.
Individual doses of 2 mL or less may be given on a daily basis until the calculated total amount required has been reached. Dexferrum is given undiluted at a slow gradual rate not to exceed 50 mg (1 mL) per minute.
If no adverse reactions are observed, Dexferrum can be given according to the following schedule until the calculated total amount required has been reached. Each day's dose should ordinarily not exceed 0.5 mL (25 mg of iron) for infants under 5 kg (11 lbs); 1 mL (50 mg of iron) for children under 10 kg (22 lbs); and 2 mL (100 mg of iron) for other patients.
NOTE: Do not mix Dexferrum with other medications or add to parenteral nutrition solutions for intravenous infusion.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Login To Your Free Account